S-1/A: IMAC Holdings Files Amendment for Potential Resale of 35 Million Shares

IMAC Holdings has filed an amendment to its registration statement for the potential resale of up to 35,007,025 shares of common stock by Keystone Capital Partners, LLC.

Summary

• IMAC Holdings has filed an amendment to its registration statement related to a potential resale of up to 35,007,025 shares of common stock.
• The shares are to be resold by Keystone Capital Partners, LLC, as part of a Common Stock Purchase Agreement.
• This agreement establishes an equity line of credit, allowing IMAC to potentially receive up to $60 million.
• The shares include an initial commitment of 164,000 shares, $1 million in back-end commitment shares, and up to $60 million in purchase shares.
• The actual number of shares issued will depend on the market price of IMAC's common stock at the time of sale.
• IMAC will not receive any proceeds from the resale of shares by Keystone, but may receive up to $60 million from the sale of purchase shares to Keystone.
• The company is required to use 25% of any net proceeds from the sale of shares to redeem certain preferred stock.
• The remaining proceeds are intended for working capital and general corporate purposes.
• IMAC is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is potential for significant capital through the equity financing agreement, the company faces serious challenges including potential delisting from Nasdaq and delays in financial reporting. The company's shift to proteomics is a positive, but the financial risks and compliance issues weigh heavily on the overall sentiment.

Positives

• The committed equity financing agreement provides IMAC with a potential source of capital up to $60 million.
• The company has the flexibility to sell shares to Keystone at its discretion, based on market conditions.
• The company has repaid all outstanding promissory notes as of November 14, 2024.

Negatives

• The company will not receive any proceeds from the resale of shares by Keystone.
• The actual proceeds from the sale of purchase shares to Keystone may be less than $60 million.
• The company is subject to a one-year Panel Monitor by Nasdaq.
• The company received a notice from Nasdaq on January 21, 2025, that it no longer complies with the Minimum Equity Rule and may be delisted.
• The company has experienced delays in filing its quarterly reports with the SEC.

Risks

• The actual number of shares issued and the proceeds received under the Purchase Agreement are uncertain.
• The company may not have access to the full $60 million available under the Purchase Agreement.
• Sales of shares to Keystone may cause the price of IMAC's common stock to decline.
• Investors who buy shares from Keystone at different times will likely pay different prices.
• Future resales and issuances of shares may cause the market price of the shares to drop significantly.
• The company has broad discretion over the use of proceeds from sales of common stock.
• The company may be delisted from Nasdaq due to non-compliance with the Minimum Equity Rule.
• The company has a history of not meeting filing deadlines.

Future Outlook

The company intends to use the net proceeds for working capital and other general corporate purposes, and may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets.

Industry Context

The document highlights IMAC's shift towards proteomic products for oncology treatment decisions, reflecting a growing trend in personalized medicine and targeted therapies. The company's focus on protein signaling, rather than genes, aligns with the increasing recognition of the importance of proteomics in cancer treatment.

Comparison to Industry Standards

• The company's Reverse Phase Protein Array (RPPA) technology is a unique and patented platform, which is a differentiator in the proteomics market.
• The company's initial focus on breast cancer with the Ignite RPPA Assay is a common approach for companies entering the oncology diagnostics market.
• The expansion of the test to include other cancers such as ovarian, endometrial, and head & neck cancers in 2025, and colorectal, prostate, pancreatic, and lung cancers in 2026, is a typical strategy for growth in the diagnostics industry.
• The company's plan to obtain reimbursement from Medicare and third-party payors is a standard practice for medical testing companies.
• The company's compassionate care program is a unique approach to ensure access to its tests for those without insurance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares.
• Shareholders face the risk of delisting from Nasdaq.
• Employees may be impacted by the company's financial challenges.
• Customers may benefit from the company's new proteomic products.
• Creditors may be impacted by the company's financial challenges.

Next Steps

• The company intends to appeal Nasdaq's delisting determination.
• The company will continue to work towards obtaining reimbursement for its Ignite proteomics test.
• The company plans to launch the Ignite RPPA Pan-Tumor Assay 1.0 in 2025 and the Ignite RPPA Pan-Tumor Assay 2.0 in 2026.

Key Dates

Keywords

equity financing, common stock, resale, Keystone Capital Partners, registration statement, preferred stock, Nasdaq, delisting, proteomics, cancer treatment